Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab (ZW25) in Advanced HER2-Expressing Cancers
NCT02892123Phase 1Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Sep 2016
- Primary completion
- Oct 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of zanidatamab in HER2-positive breast cancer, gastroesophageal adenocarcinoma, HER2-positive biliary tract cancer and 3 more (6 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoints: Dose-Limiting Toxicities up to 8 months and Adverse Events up to 2 years. Started Sep 2016; status: completed.
02
Drugs
zanidatamab
03
Conditions
HER2-positive breast cancergastroesophageal adenocarcinomaHER2-positive biliary tract cancercolorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02892123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02892123.